Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug RVU120 gets extended trial for ongoing patients

NCT ID NCT06987058

Disease control Sponsor: Ryvu Therapeutics SA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 18, 2026 · Updated 7 times

Summary

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients can stay on treatment. Participants must have completed at least 5 cycles in the parent study and have no other available options.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RVU120 (a drug that blocks certain proteins in cancer cells)
What this could lead to
If successful, this study could show that long-term RVU120 treatment is safe and helps control advanced solid tumors, AML, or high-risk MDS.
What could go wrong
This is a small rollover study (10 people) with no control group, so results may not apply broadly. Side effects are possible, and the drug may stop working over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 14 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The participant is enrolled in a RVU120 clinical study and receiving RVU120-based treatment given alone or in combination for at least 5 cycles. 2. The participant is currently benefiting from, and expected to continue to benefit from, RVU120-based treatment according to the criteria set out in the parent study protocol and according to the judgment of the investigator and sponsor. 3. The participant does not have access to commercially available comparator anticancer therapy. 4. Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 5. The participant signed the rollover study ICF prior to any study-related procedure or study data collection. 6. The participant agrees not to donate blood during study participation and until 28 weeks (\~6.5 months) after the last dose. 7. The investigator considers the participant to be eligible for participation in the rollover study. Exclusion Criteria: 1. Presence of toxicity that cannot be adequately managed. 2. Concurrent participation in any therapeutic clinical study other than the parent study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukaemia (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes neoplasm Neoplasm Metastasis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukaemia (AML) Advanced solid tumors High risk myelodysplastic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CWBK UCK Ośrodek Badań Klinicznych Wczesnych Faz

    Gdansk, Poland

  • Hôpital Haut-Lévêque- CHU de Bordeaux, Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire

    Pessac, France

  • Hôpital l'Archet 1 - CHU de Nice; Service Hématologie Clinique

    Nice, France

  • M2M Med Sp. Z o.o.

    Chorzów, Poland

  • Pratia Hematologia Sp. z o.o. Pratia Onkologia Katowice

    Katowice, Poland

  • SPZOZ Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Terapii Komórkowych i Chorób Wewnętrznych

    Wroclaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.